On April 5, 2024 RenovoRx, Inc. ("RenovoRx" or the "Company") (Nasdaq: RNXT), a clinical-stage biopharmaceutical company developing novel precision oncology therapies based on a local drug-delivery platform, reported that Shaun Bagai, RenovoRx’s Chief Executive Officer, will present at the Canaccord Genuity 2024 Horizons in Oncology Virtual Conference to be held on April 15, 2024 (Press release, Renovorx, APR 5, 2024, View Source [SID1234641827]).
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
Mr. Bagai will meet with investors and participate in a panel discussion hosted by Bill Maughan, Senior Analyst at Canaccord Genuity. The panel is titled "Delivering High Local Concentrations of Chemotherapy for Solid Tumors," and takes place on Monday, April 15, 2024, at 8:00 am ET. He will discuss the initial positive interim analysis in the Company’s pivotal Phase III TIGeR-PaC clinical trial. The study is evaluating the Company’s lead product candidate, RenovoGem, and proprietary Trans-Arterial Micro-Perfusion (TAMP) therapy platform for the treatment of locally advanced pancreatic cancer.
Mr. Bagai will also discuss the Company’s plans for 2024 and beyond as well as recent milestones, including the completion of a private placement in January 2024. The private placement extended cash runway, allowing the Company to advance towards its near-term key milestone of a second interim analysis for TIGeR-PaC that will be triggered by the 52nd event (death), which is estimated to occur in late 2024.
CG 2024 Horizons in Oncology Virtual Conference
Date: April 15, 2024
Time: 8:00am ET – 8:50am ET
Speaker: Shaun Bagai, CEO
Location: Virtual
To schedule a one-on-one investor meeting with Mr. Bagai, please contact your Canaccord representative or KCSA Strategic Communications at [email protected].